Related Experiment Video

Updated: Jul 10, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

Simvastatin may improve myocardial perfusion abnormality in slow coronary flow

Mahmut Cakmak1, Halil Tanriverdi, Nazmiye Cakmak

  • 1Department of Cardiology, Siyami Ersek Cardiac and Thoracic Surgery Center, Istanbul, Turkey. cakmakmn@yahoo.com

Cardiology
|October 16, 2007
PubMed

Insights

Simvastatin treatment significantly improved myocardial perfusion in patients experiencing slow coronary flow (SCF), a microvascular disorder. This study highlights statins as a potential therapeutic option for enhancing coronary blood flow in these patients.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Slow coronary flow (SCF) is a coronary microvascular disorder.
  • Pathogenesis may involve endothelial dysfunction, atherosclerosis, and inflammation.
  • Investigating therapeutic interventions for SCF is crucial.

Purpose of the Study:

  • To evaluate the impact of statin therapy on myocardial perfusion in patients with SCF.
  • To assess changes in coronary flow patterns and perfusion abnormalities.
  • To determine the efficacy of simvastatin in managing SCF.

Main Methods:

  • 97 patients with SCF were enrolled.
  • Coronary flow assessed using Thrombolysis in Myocardial Infarction (TIMI) frame count.
  • Myocardial perfusion imaging and lipid profiles obtained pre- and post-6 months of simvastatin (40 mg daily).

Main Results:

  • A significant positive correlation was found between TIMI frame count and basal reversibility score (r = 0.84, p = 0.0001).
  • Simvastatin treatment led to significant improvement in myocardial perfusion abnormalities.
  • Lipid parameters were monitored throughout the treatment period.

Conclusions:

  • Simvastatin effectively improved myocardial perfusion in patients with slow coronary flow.
  • These findings suggest statins as a viable treatment for enhancing coronary microvascular function.
  • Further research may explore long-term effects and optimal statin regimens for SCF.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...